Hangzhou Hanx Biopharmaceuticals, Ltd.
Clinical trials sponsored by Hangzhou Hanx Biopharmaceuticals, Ltd., explained in plain language.
-
New Dual-Action antibody shows promise for tough lymphoma cases
Disease control CompletedThis study tested an experimental drug called HX009 in 48 adults with lymphoma that returned or didn't respond to standard treatments. HX009 is a special antibody designed to attack cancer cells from two angles (CD47 and PD-1) to boost the immune system's fight. The main goal was…
Phase: PHASE1, PHASE2 • Sponsor: Hangzhou Hanx Biopharmaceuticals, Ltd. • Aim: Disease control
Last updated Jun 22, 2026 12:09 UTC
-
New Dual-Action antibody shows promise in advanced cancer trial
Disease control CompletedThis study tested a new drug called HX009 in 20 people with advanced solid tumors that had stopped responding to standard treatments. HX009 is a bifunctional antibody designed to help the immune system attack cancer cells. The main goal was to see if the drug could shrink tumors …
Phase: PHASE2 • Sponsor: Hangzhou Hanx Biopharmaceuticals, Ltd. • Aim: Disease control
Last updated Jun 17, 2026 12:06 UTC